Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

SA Transcripts 162.13K Followers Follow Allogene Therapeutics, Inc. ( ALLO ) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 8:00 AM EDT Company Participants Zachary Roberts - President, CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Citigroup Inc., Research Division All right. Good morning. I'm Sam Semenkow, one of the senior biotech analysts here at Citi, and it's my pleasure to be hosting Allogene Therapeutics at Citi's 2026 Biopharma Back to School Summit. I'm joined this morning by -- with Zach Roberts, President and CEO of Allogene. Zach, welcome, and thank you so much for being here. Zachary Roberts President, CEO & Director Thank you very much, Sam. Great to be here. Question-and-Answer Session Samantha Semenkow Citigroup Inc., Research Division So, why don't we just start a little bit high level on the business. You've made a ton of progress this year on the pipeline. Could you just level set for the audience where the company stands today and what we can expect throughout the rest of the year? Zachary Roberts President, CEO & Director Yes. So, it's been a very productive year in 2026 so far. Beginning with our leading program, we released some data in April from an interim futility analysis. We also are moving very briskly through enrollment in our Phase I program, which is a novel therapeutic CAR T cell product in autoimmune disease indications. And we'll have some data from that program later this year at an upcoming conference. And that's setting us up for a very exciting busy year of catalysts in 2027. Samantha Semenkow Citigroup Inc., Research Division Yes, absolutely. And so you recently stepped into that CEO role. Congratulations. I'm wondering how you're thinking about the business from that perspective? What do you bring from the company in this new seat? And how should we